We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+6.63%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$870M
AUM Growth
+$27M
Cap. Flow
+$16.7M
Cap. Flow %
1.92%
Top 10 Hldgs %
32.2%
Holding
103
New
12
Increased
47
Reduced
28
Closed
15

Top Buys

Rank Stock Value
1
IQV icon
IQVIA
IQV
+$16.5M
2
WGS icon
GeneDx Holdings
WGS
+$13.7M
3
DHR icon
Danaher
DHR
+$9.08M
4
DXCM icon
DexCom
DXCM
+$7.49M
5
ASND icon
Ascendis Pharma A/S
ASND
+$6.86M

Top Sells

Rank Stock Value
1
BDX icon
Becton Dickinson
BDX
+$27.6M
2
UNH icon
UnitedHealth
UNH
+$26.3M
3
SYK icon
Stryker
SYK
+$10.2M
4
GILD icon
Gilead Sciences
GILD
+$9.29M
5
PODD icon
Insulet
PODD
+$7.14M

Sector Composition

Rank Sector Weight
1 Healthcare 99.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NRIX icon
76
Nurix Therapeutics
NRIX
$2.76B
$2.6M 0.3%
228,271
-122,149
-35% -$1.32M
UTHR icon
77
United Therapeutics
UTHR
$21.9B
$2.53M 0.29%
8,811
-1,421
-14% -$425K
URGN icon
78
UroGen Pharma
URGN
$2.39B
$2.42M 0.28%
176,702
-216,451
-55% -$2.08M
APGE icon
79
Apogee Therapeutics
APGE
$10.2B
$2.41M 0.28%
55,404
+8,741
+19% +$333K
PGEN icon
80
Precigen
PGEN
$2.45B
$2.19M 0.25%
1,542,823
-1,648,520
-52% -$2.34M
CRNX icon
81
Crinetics Pharmaceuticals
CRNX
$8.96B
$2.11M 0.24%
73,412
+9,472
+15% +$293K
LUNG icon
82
Pulmonx
LUNG
$98.4M
$1.57M 0.18%
605,029
-6,846
-1% -$27K
ARDX icon
83
Ardelyx
ARDX
$1.03B
$1.18M 0.14%
301,086
+91,505
+44% +$377K
ANNX icon
84
Annexon
ANNX
$873M
$970K 0.11%
404,194
+52,758
+15% +$106K
ATYR
85
aTyr Pharma
ATYR
$53M
$761K 0.09%
+150,000
New +$590K
MASS icon
86
908 Devices
MASS
$414M
$713K 0.08%
+100,000
New +$556K
ENTX icon
87
Entera Bio
ENTX
$138M
$676K 0.08%
355,822
-83,810
-19% -$166K
FOCL
88
EDAP TMS S.A.
FOCL
$178M
$255K 0.03%
154,832
– –
BDX icon
89
Becton Dickinson
BDX
$50B
– –
-120,283
Closed -$27.6M
GH icon
90
Guardant Health
GH
$22.2B
– –
-89,329
Closed -$3.81M
ICAD
91
DELISTED
iCAD Inc
ICAD
– –
-781,670
Closed -$1.61M
INSM icon
92
Insmed
INSM
$28.9B
– –
-37,901
Closed -$2.89M
IRWD icon
93
Ironwood Pharmaceuticals
IRWD
$714M
– –
-205,086
Closed -$301K
KROS icon
94
Keros Therapeutics
KROS
$222M
– –
-217,753
Closed -$2.22M
MRVI icon
95
Maravai LifeSciences
MRVI
$861M
– –
-660,000
Closed -$1.46M
NAMS icon
96
NewAmsterdam Pharma
NAMS
$3.33B
– –
-100,955
Closed -$2.07M
ORIC icon
97
Oric Pharmaceuticals
ORIC
$1.43B
– –
-203,006
Closed -$1.13M
PCVX icon
98
Vaxcyte
PCVX
$8.88B
– –
-93,431
Closed -$3.53M
RLAY icon
99
Relay Therapeutics
RLAY
$4.4B
– –
-188,052
Closed -$493K
RMD icon
100
ResMed
RMD
$32.8B
– –
-22,622
Closed -$5.06M
1 2 3
4
5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q2 2025 Portfolio in Review

As of Q2 2025, Parkman Healthcare Partners held 103 positions worth $870M, up 3.2% from $843M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Parkman Healthcare Partners's Q2 2025 filing shows 12 new, 47 increased, 28 reduced and 15 closed positions. Its largest new stake was IQVIA: 109,500 shares worth $17.3M. The largest sale was Becton Dickinson, an estimated $27.6M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

  • Parkman Healthcare Partners's largest Q2 2025 buy was IQVIA: 109,500 shares worth $17.3M.
  • Parkman Healthcare Partners added most to Danaher in Q2 2025, an estimated $9.08M increase.
  • Parkman Healthcare Partners's biggest Q2 2025 reduction was Stryker, cutting an estimated $10.2M.
  • Parkman Healthcare Partners fully exited Becton Dickinson in Q2 2025, selling an estimated $27.6M.
  • Parkman Healthcare Partners's ten largest holdings make up 32% of its $870M portfolio in Q2 2025.
  • Parkman Healthcare Partners opened 12 new positions and closed 15 in Q2 2025.
  • Parkman Healthcare Partners's portfolio value rose 3.2% quarter-over-quarter to $870M.

Based on Parkman Healthcare Partners's 13F filing for Q2 2025, filed 14 Aug 2025.